Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents.

ABSTRACT:

Importance

The emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2 has led to increases in both infections and hospitalizations among adolescents. Little is known about the effectiveness of the BNT162b2 vaccine in adolescents in the general population, as opposed to a clinical trial population.

Objective

To estimate the effectiveness of the BNT162b2 vaccine in adolescents aged 12 to 18 years.

Design, setting, and participants

This was a matched case-control study among adolescents (aged 12-18 years) who had results from a SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test. Immunization histories, relevant clinical data, and RT-PCR test results were obtained from the Yale New Haven Health System's medical records between June 1, 2021, and Aug

SUBMITTER: Oliveira CR 

PROVIDER: S-EPMC8895259 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature